Bone morphogenetic protein 2 stimulates noncanonical smad2/3 signaling via the bmp type 1a receptor in gonadotrope-like cells: Implications for FSH synthesis

Endocrinology

Volumn 155, Issue 5, 2014, Pages 1970-1981

  Wang, Ying ^a   Ho, Catherine C ^a   Bang, Eunjin ^a   Rejon, Carlis A ^a   Libasci, Vanessa ^a   Pertchenko, Pavel ^a   Hébert, Terence E ^a   Bernard, Daniel J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXY 1 METHYLTETRALIN; ACTIVIN; ALK7 PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; DNA BINDING PROTEIN; FOLLITROPIN; GLYCINE; SERINE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD8 PROTEIN; THREONINE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; GONADOTROPIN SECRETING CELL; HORMONE SYNTHESIS; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ACTIVINS; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; CELL LINE; FOLLICLE STIMULATING HORMONE, BETA SUBUNIT; GENE SILENCING; GENES, REPORTER; GONADOTROPHS; HUMANS; MICE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION, GENETIC;

EID: 84899436546     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1741     Document Type: Article

References (79)

1. Bernard DJ, Fortin J, Wang Y, Lamba P. Mechanisms of FSH synthesis: what we know, what we don't, and why you should care. Fertil Steril. 2010;93:2465-2485.
2. Huhtaniemi IT, Themmen AP. Mutations in human gonadotropin and gonadotropin-receptor genes. Endocrine. 2005;26:207-217. (Pubitemid 41271085)
3. Themmen AP. An update of the pathophysiology of human gonadotrophin subunit and receptor gene mutations and polymorphisms. Reproduction. 2005;130:263-274. (Pubitemid 41320751)
4. Kumar TR, Wang Y, Lu N, Matzuk MM. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat Genet. 1997;15:201-204. (Pubitemid 27061644)
5. Dierich A, Sairam MR, Monaco L, et al. Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA. 1998;95:13612-13617. (Pubitemid 28523020)
6. Weiss J, Guendner MJ, Halvorson LM, Jameson JL. Transcriptional activation of the follicle-stimulating hormone β subunit gene by activin. Endocrinology. 1995;136:1885-1891.
7. Bernard DJ. Both SMAD2 and SMAD3 mediate activin-stimulated expression of the follicle-stimulating hormone β subunit in mouse gonadotrope cells. Mol Endocrinol. 2004;18:606-623. (Pubitemid 38328206)
8. Suszko MI, Lo DJ, Suh H, Camper SA, Woodruff TK. Regulation of the rat follicle-stimulating hormone β-subunit promoter by activin. Mol Endocrinol. 2003;17:318-332. (Pubitemid 36315627)
9. Lewis KA, Gray PC, Blount AL, et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature. 2000;404:411-414. (Pubitemid 30164345)
10. Chapman SC, Bernard DJ, Jelen J, Woodruff TK. Properties of inhibin binding to βglycan, InhBP/p120 and the activin type II receptors. Mol Cell Endocrinol. 2002;196:79-93. (Pubitemid 35254108)
11. Xu J, McKeehan K, Matsuzaki K, McKeehan WL. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism. J Biol Chem. 1995;270:6308-6313.
12. Lebrun JJ, Vale WW. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. Mol Cell Biol. 1997;17:1682-1691. (Pubitemid 27097397)
13. Huang HJ, Wu JC, Su P, Zhirnov O, Miller WL. A novel role for bone morphogenetic proteins in the synthesis of follicle-stimulating hormone. Endocrinology. 2001;142:2275-2283. (Pubitemid 32473081)
14. Lee KB, Khivansara V, Santos MM, et al. Bone morphogenetic protein 2 and activinAsynergistically stimulate follicle-stimulating hormone β subunit transcription. J Mol Endocrinol. 2007;38:315-330. (Pubitemid 46351612)
15. Otsuka F, Shimasaki S. A novel function of bone morphogenetic protein-15 in the pituitary: selective synthesis and secretion of FSH by gonadotropes. Endocrinology. 2002;143:4938-4941. (Pubitemid 35397634)
16. Takeda M, Otsuka F, Takahashi H, et al. Interaction between gonadotropin- releasing hormone and bone morphogenetic protein-6 and -7 signaling in LβT2 gonadotrope cells. Mol Cell Endocrinol. 2012;348:147-154.
17. Takeda M, Otsuka F, Suzuki J, et al. Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas. Biochem Biophys Res Commun. 2003; 306:812-818. (Pubitemid 36776203)
18. Faure MO, Nicol L, Fabre S, et al. BMP-4 inhibits follicle-stimulating hormone secretion in ewe pituitary. J Endocrinol. 2005;186: 109-121. (Pubitemid 41015669)
19. Galloway SM, McNatty KP, Cambridge LM, et al. Mutations in an oocyte-derived growth factor gene (BMP15) cause increased ovulation rate and infertility in a dosage-sensitive manner. Nat Genet. 2000;25:279-283. (Pubitemid 30437312)
20. Nicol L, FaureMO,McNeilly JR, Fontaine J, Taragnat C, McNeilly AS. Bone morphogenetic protein-4 interacts with activin andGnRH to modulate gonadotrophin secretion in LβT2 gonadotrophs. J Endocrinol. 2008;196:497-507. (Pubitemid 351425505)
21. Young JM, Juengel JL, Dodds KG, et al. The activin receptor-like kinase 6 Booroola mutation enhances suppressive effects of bone morphogenetic protein 2 (BMP2), BMP4, BMP6 and growth and differentiation factor-9 on FSH release from ovine primary pituitary cell cultures. J Endocrinol. 2008;196:251-261. (Pubitemid 351298510)
22. Miyazono K, Kamiya Y, MorikawaM.Bone morphogenetic protein receptors and signal transduction. J Biochem. 2010;147:35-51.
23. KawabataM,ImamuraT, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 1998;9:49-61. (Pubitemid 28280536)
24. Yamashita H, ten Dijke P, Franzén P, Miyazono K, Heldin CH. Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-β. J Biol Chem. 1994;269: 20172-20178.
25. Attisano L, Wrana JL, Montalvo E, Massagué J. Activation of signalling by the activin receptor complex. Mol Cell Biol. 1996;16: 1066-1073. (Pubitemid 26061678)
26. Greenwald J, Groppe J, Gray P, et al. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell. 2003;11:605-617. (Pubitemid 36385117)
27. Lin SJ, Lerch TF, CookRW,Jardetzky TS, Woodruff TK. The structural basis of TGF-β, bone morphogenetic protein, and activin ligand binding. Reproduction. 2006;132:179-190. (Pubitemid 44269702)
28. Allendorph GP, ValeWW,Choe S. Structure of the ternary signaling complex of a TGF-β superfamily member. Proc Natl Acad Sci USA. 2006;103:7643-7648.
29. ten Dijke P, Yamashita H, Sampath TK, et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein- 4. J Biol Chem. 1994;269:16985-16988. (Pubitemid 24204009)
30. Rosenzweig BL, Imamura T, Okadome T, et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA. 1995;92:7632-7636.
31. NoheA, Hassel S, EhrlichM,et al. Themodeof bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem. 2002;277:5330-5338. (Pubitemid 34968578)
32. Nohe A, Keating E, Underhill TM, Knaus P, Petersen NO. Effect of the distribution and clustering of the type I A BMP receptor (ALK3) with the type II BMP receptor on the activation of signalling pathways. J Cell Sci. 2003;116:3277-3284. (Pubitemid 37038976)
33. Yu PB, Beppu H, Kawai N, Li E, Bloch KD. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J Biol Chem. 2005;280:24443-24450. (Pubitemid 40934529)
34. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood. 2007;109: 1953-1961. (Pubitemid 46348192)
35. Ho CC, Bernard DJ. Bone morphogenetic protein 2 signals via BMPR1Ato regulate murine follicle-stimulating hormone β subunit transcription. Biol Reprod. 2009;81:133-141.
36. Kretzschmar M, Liu F, Hata A, Doody J, Massagué J. The TGF-β family mediator Smad1 is phosphorylated directly and activated functionally by theBMPreceptor kinase. Genes Dev. 1997;11:984- 995. (Pubitemid 27199878)
37. Souchelnytskyi S, Tamaki K, Engström U, Wernstedt C, ten Dijke P, HeldinCH.Phosphorylation of Ser465 and Ser467 in theCterminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-β signaling. J Biol Chem. 1997;272:28107- 28115. (Pubitemid 27473621)
38. Ho CC, Zhou X, Mishina Y, Bernard DJ. Mechanisms of bone morphogenetic protein 2 (BMP2) stimulated inhibitor ofDNAbinding 3 (Id3) transcription. Mol Cell Endocrinol. 2011;332:242-252.
39. HoCC,Bernard DJ. Bone morphogenetic protein 2 acts via inhibitor of DNA binding proteins to synergistically regulate follicle-stimulating hormone β transcription with activin A. Endocrinology. 2010;151:3445-3453.
40. Wang Y, Bernard DJ. Activin A induction of murine and ovine follicle-stimulating hormone β transcription is SMAD-dependent and TAK1 (MAP3K7)/p38 MAPK-independent in gonadotropelike cells. Cell Signal. 2012;24:1632-1640.
41. Tran S, Lamba P, Wang Y, Bernard DJ. SMADs and FOXL2 synergistically regulate murine FSHβ transcription via a conserved proximal promoter element. Mol Endocrinol. 2011;25:1170-1183.
42. Lamba P, Wang Y, Tran S, et al. Activin A regulates porcine folliclestimulating hormone β subunit transcription via cooperative actions of SMADs and FOXL2. Endocrinology. 2010;151:5456- 5467.
43. Lamba P, Fortin J, Tran S, Wang Y, Bernard DJ. A novel role for the forkhead transcription factorFOXL2in activin A-regulated folliclestimulating hormone β subunit transcription. Mol Endocrinol. 2009;23:1001-1013.
44. Lamba P, Santos MM, Philips DP, Bernard DJ. Acute regulation of murine follicle-stimulating hormone β subunit transcription by activin A. J Mol Endocrinol. 2006;36:201-220. (Pubitemid 43273676)
45. McGillivray SM, Thackray VG, Coss D, Mellon PL. Activin and glucocorticoids synergistically activate follicle-stimulating hormone β subunit gene expression in the immortalized LβT2 gonadotrope cell line. Endocrinology. 2007;148:762-773. (Pubitemid 46143177)
46. Corpuz PS, Lindaman LL, Mellon PL, Coss D. FoxL2 is required for activin induction of the mouse and human follicle-stimulating hormone β subunit genes. Mol Endocrinol. 2010;24:1037-1051.
47. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998;17:3091-3100. (Pubitemid 28254381)
48. Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein- specific response elements in the Id1 promoter. J Biol Chem. 2002;277:4883-4891. (Pubitemid 34968524)
49. Tournay O, Benezra R. Transcription of the dominant-negative helix- loop-helix protein Id1 is regulated by a protein complex containing the immediate-early response gene Egr-1. Mol Cell Biol. 1996;16:2418-2430. (Pubitemid 26123764)
50. Liu F, Ventura F, Doody J, Massagué J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol. 1995;15:3479-3486.
51. Rejon CA, Hancock MA, Li YN,Thompson TB, Hébert TE, Bernard DJ. Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells. Cell Signal. 2013;25:2717-2726.
52. Rejon CA, Ho CC, Wang Y, Zhou X, Bernard DJ, Hébert TE. Cycloheximide inhibits follicle-stimulating hormone β subunit transcription by blocking de novo synthesis of the labile activin type II receptor in gonadotrope cells. Cell Signal. 2013;25:1403-1412.
53. Alarid ET, Windle JJ, Whyte DB, Mellon PL. Immortalization of pituitary cells at discrete stages of development by directed oncogenesis in transgenic mice. Development. 1996;122:3319-3329. (Pubitemid 26371995)
54. Wang Y, Libasci V, Bernard DJ. Activin A induction of FSHβ subunit transcription requires SMAD4 in immortalized gonadotropes. J Mol Endocrinol. 2010;44:349-362.
55. Boyd FT, Massagué J. Transforming growth factor-β inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem. 1989;264:2272-2278. (Pubitemid 19057703)
56. Wang Y, Fortin J, Lamba P, et al. Activator protein-1 and smad proteins synergistically regulate human follicle-stimulating hormone β-promoter activity. Endocrinology. 2008;149:5577-5591.
57. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFss and BMP pathways. Cell Signal. 2011;23:1831-1842.
58. Inman GJ, Nicolás FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65-74. (Pubitemid 34680517)
59. Bernard DJ, Lee KB, Santos MM. Activin B can signal through both ALK4 and ALK7 in gonadotrope cells. Reprod Biol Endocrinol. 2006;4:52.
60. Tsuchida K, Nakatani M, Yamakawa N, Hashimoto O, Hasegawa Y, Sugino H. Activin isoforms signal through type I receptor serine/ threonine kinase ALK7. Mol Cell Endocrinol. 2004;220:59-65. (Pubitemid 38757881)
61. Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008;4:33-41. (Pubitemid 350273653)
62. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408:297-315.
63. Cuny GD, Yu PB, Laha JK, et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008;18:4388-4392.
64. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two majorSmadpathways inTGF-β superfamily signalling. Genes Cells. 2002;7:1191-1204. (Pubitemid 36024597)
65. Chen YG, Hata A, Lo RS, et al. Determinants of specificity in TGF-β signal transduction. Genes Dev. 1998;12:2144-2152. (Pubitemid 28348038)
66. Lo RS, Chen YG, Shi Y, Pavletich NP, Massagué J. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-β receptors. EMBO J. 1998;17:996-1005. (Pubitemid 28077654)
67. Akiyama S, Katagiri T, Namiki M, et al. Constitutively active BMP type I receptors transduce BMP-2 signals without the ligand in C2C12 myoblasts. Exp Cell Res. 1997;235:362-369. (Pubitemid 27398394)
68. Zhu HJ, SizelandAM.Apivotal role for the transmembrane domain in transforming growth factor-β receptor activation. J Biol Chem. 1999;274:11773-11781.
69. Macías-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem. 1998;273:25628-25636. (Pubitemid 28475783)
70. Wrana JL, Attisano L, Cárcamo J, et al. TGF β signals through a heteromeric protein kinase receptor complex. Cell. 1992;71:1003- 1014.
71. Zou H, Wieser R, Massagué J, Niswander L. Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev. 1997;11:2191-2203. (Pubitemid 27387970)
72. Wieser R, Wrana JL, Massagué J. GS domain mutations that constitutively activate T β R-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 1995;14:2199-2208.
73. Murakami M, Kawachi H, Ogawa K, Nishino Y, Funaba M. Receptor expression modulates the specificity of transforming growth factor-β signaling pathways. Genes Cells. 2009;14:469-482.
74. Holtzhausen A, Golzio C, How T, et al. Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J. 2014;28:1248-1267.
75. Liu IM, Schilling SH, Knouse KA, Choy L, Derynck R, Wang XF. TGF β-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGF β switch.EMBOJ. 2009; 28:88-98.
76. Wrighton KH, Lin X, Yu PB, Feng XH. Transforming growth factor β can stimulate Smad1 phosphorylation independently of bone morphogenic protein receptors. J Biol Chem. 2009;284:9755-9763.
77. Persson U, Izumi H, Souchelnytskyi S, et al. The L45 loop in type I receptors for TGF-β family members is a critical determinant in specifying Smad isoform activation. FEBS Lett. 1998;434:83-87. (Pubitemid 28404667)
78. Feng XH, Derynck R. A kinase subdomain of transforming growth factor-β (TGF-β) type I receptor determines the TGF-β intracellular signaling specificity. EMBO J. 1997;16:3912-3923. (Pubitemid 27281007)
79. Itoh S, Thorikay M, Kowanetz M, et al. Elucidation of Smad requirement in transforming growth factor-β type I receptor-induced responses. J Biol Chem. 2003;278:3751-3761. (Pubitemid 36801101)